Arzerra Side Effects

Generic name: ofatumumab

Medically reviewed by Drugs.com. Last updated on Jun 4, 2024.

Note: This document provides detailed information about Arzerra Side Effects associated with ofatumumab. Some dosage forms listed on this page may not apply specifically to the brand name Arzerra.

Applies to ofatumumab: solution.

Important warnings This medicine can cause some serious health issues

Intravenous route (solution)

Hepatitis B Virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, including ofatumumab, in some cases resulting in fulminant hepatitis, hepatic failure, and death.

Progressive Multifocal Leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including ofatumumab.

Serious side effects of Arzerra

Along with its needed effects, ofatumumab (the active ingredient contained in Arzerra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ofatumumab:

More common side effects

• black, tarry stools
• bloating or swelling of the face, arms, hands, lower legs, or feet
• blurred vision
• body aches or pain
• chest pain or tightness
• chills
• confusion
• cough producing mucus
• difficult or labored breathing
• dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
• ear congestion
• facial swelling
• fainting
• fast heartbeat
• feeling of warmth
• headache
• hives or welts, itching, or skin rash
• increased sweating
• lightheadedness
• loss of voice
• lower back or side pain
• nausea or vomiting
• painful blisters on the trunk of the body
• painful or difficult urination
• pale skin
• rapid, shallow breathing
• redness of the face, neck, arms, and occasionally, upper chest
• runny or stuffy nose
• sneezing
• sore throat
• tingling of the hands or feet
• trouble breathing
• ulcers, sores, or white spots in the mouth
• unusual bleeding or bruising
• unusual tiredness or weakness
• unusual weight gain or loss
• bladder pain
• bloody or cloudy urine
• body aches or pain
• chills
• cough
• difficult, burning, or painful urination
• dryness or soreness of throat
• ear congestion
• fever
• flushing, redness of skin
• frequent urge to urinate
• hoarseness
• joint pain
• loss of voice
• lower back or side pain
• muscle aches
• pain or tenderness around eyes and cheekbones
• pain, itching, swelling of the skin
• runny nose
• sneezing
• sore throat
• stuffy or runny nose
• sweating
• swollen joints
• tender, swollen glands in the neck
• trouble in swallowing
• unusually warm skin
• voice changes
• vomiting

Less common side effects

• fast, pounding, or irregular heartbeat or pulse
• nervousness
• pounding in the ears
• slow heartbeat

Incidence not known

• blistering, peeling, or loosening of the skin
• dark urine
• diarrhea
• fluid-filled skin blisters
• joint or muscle pain
• light-colored stools
• no blood pressure or pulse
• red skin lesions, often with a purple center
• red, irritated eyes
• sensitivity to the sun
• skin thinness
• stopping of heart
• unconsciousness
• yellow eyes or skin

Check with your doctor immediately if any of the following side effects occur while taking ofatumumab:

Other side effects of Arzerra

Some side effects of ofatumumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• back pain
• muscle aches
• redness of the skin
• trouble sleeping

Less common side effects

• bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
• muscle spasms
• pain or tenderness around the eyes and cheekbones

For healthcare professionals

Applies to ofatumumab: intravenous solution, subcutaneous solution.

Hematologic adverse events

• Very common (10% or more): Neutropenia (up to 27%), anemia (up to 18%)
• Common (1% to 10%): Leukopenia, febrile neutropenia, thrombocytopenia
• Uncommon (0.1% to 1%): Agranulocytosis, coagulopathy, red cell aplasia, lymphopenia^[Ref]

Respiratory

• Very common (10% or more): Upper respiratory tract infection (up to 19%), pneumonia (up to 23%), cough (up to 19%), dyspnea (up to 14%), bronchitis (up to 11%), lower respiratory tract infection
• Common (1% to 10%): Sinusitis, nasopharyngitis, bronchospasm, hypoxia, dyspnea, chest discomfort, pharyngolaryngeal pain, nasal congestion
• Uncommon (0.1% to 1%): Pulmonary edema^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (up to 18%), nausea (up to 11%)
• Common (1% to 10%): Upper abdominal pain
• Uncommon (0.1% to 1%): Small bowel obstruction^[Ref]

Dermatologic

• Very common (10% or more): Rash (e.g., rash, rash macular, rash vesicular) (up to 14%)
• Common (1% to 10%): Urticaria, hyperhidrosis, erythema, pruritus
• Uncommon (0.1% to 1%): Coagulopathy, red cell aplasia
• Postmarketing reports: Stevens-Johnson syndrome, porphyria cutanea tarda^[Ref]

Musculoskeletal

• Common (1% to 10%): Arthralgia, back pain, chills, muscle spasms, rigors^[Ref]

Psychiatric

• Common (1% to 10%): Insomnia^[Ref]

Nervous system

• Common (1% to 10%): Headache^[Ref]

Cardiovascular

• Common (1% to 10%): Hypertension, hypotension, tachycardia
• Uncommon (0.1% to 1%): Bradycardia
• Postmarketing reports: Cardiac arrest (infusion related)^[Ref]

Genitourinary

• Common (1% to 10%): Urinary tract infection^[Ref]

Hepatic

• Rare (less than 0.1%): Hepatitis B infection and reactivation^[Ref]

Hypersensitivity

• Common (1% to 10%): Anaphylactoid reactions, hypersensitivity
• Uncommon (0.1% to 1%): Anaphylactic shock, cytokine release syndrome^[Ref]

Immunologic

• Common (1% to 10%): Herpes simplex (e.g., oral herpes, herpes, herpes virus infection, genital herpes), influenza, herpes zoster, hypogammaglobulinemia, bacterial infections, viral infections, fungal infections, sepsis (e.g., sepsis, neutropenic sepsis, bacteremia, septic shock)
• Uncommon (0.1% to 1%): Immunogenicity^[Ref]

Metabolic

Very common (10% or more):

• Common (1% to 10%): Peripheral edema
• Uncommon (0.1% to 1%): Tumor lysis syndrome^[Ref]

Other

• Very common (10% or more): Pyrexia (up to 20%), fatigue (up to 15%)^[Ref]

Frequently asked questions

• How is Arzerra administered and how long to work?
• What is Arzerra used for and how does it work?

Further information

Arzerra side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer